Treatment Paradigms in R/M NPC: Evolving Role of Systemic Immunotherapy
A panelist discusses A panelist discusses how the integration of immunotherapy with chemotherapy as first-line treatment for recurrent/metastatic (R/M) nasopharyngeal carcinoma (NPC) is transforming the treatment landscape, with data from trials such as JUPITER-02 and DIPPER demonstrating improved progression-free and overall survival outcomes, while patient selection factors including performance status, comorbidities, PD-L1 expression, and EBV status remain critical considerations for optimizing therapeutic benefit in both the metastatic setting and potentially in neoadjuvant/adjuvant approaches.
Video content above is prompted by the following:
- How can current and emerging immunotherapy regimens impact the treatment landscape for metastatic NPC?
- How can integration of immunotherapy to chemotherapy up front benefit patients with R/M NPC?
- What factors will determine whether patients are suitable for this treatment?
- Please share your thoughts on the DIPPER study and other neoadjuvant/adjuvant regimens.
- What are the clinical implications?
- Please discuss treatment considerations and implications from the use of immunotherapy in NPC.
Ruxolitinib Effective as Second-Line Therapy for Chronic GvHD
July 15th 2021In an interview with Targeted Oncology, Stephanie Lee, MD, MPH, reviewed the updated data from the REACH3 trial along with the efficacy of ruxolitinib in the greater chronic graft versus host disease population.
Read More
Clinical Treatment Act Aims to Improve Survival, Close Racial Health Care Gap
June 28th 2021Across the United States, the health insurance coverage gap continues to impact millions of patients who are largely low-income or are racial minorities. After years of lobbying, Congress has passed the Clinical Treatment Act, which is legislation designed to improve access to health coverage.
Read More
